TodayBuildContextBrowseMore
stackBETAv0.1
TodayBuild a stackCommon stacksEncyclopediaPulse
Methodology
← Back to your stack
Monograph
RESEARCH GREYP-022
Longevity

5-Amino-1MQ

Small-molecule NNMT inhibitor (not a peptide). Blocks nicotinamide N-methyltransferase to preserve cellular methyl-donor pools and NAD+.

ExperimentalLongevity
Typical dose50-150 mg
Frequencydaily, oral
Half-life6h
Citations indexed14
DeliveryOral
Half-life~6h
EvidenceExperimental
Citations14
Similar compounds
Synergy checkCompare
Research grey

This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.

Mechanism

Tracked alongside peptides in biohacker stacks. Preclinical models show reduced adipose hypertrophy and improved muscle stem-cell function. No human RCTs published. Different chemistry from peptides — included here because it shows up in the same protocols.

Specifics
Body composition (lean mass)Cellular aging concerns
Caveats

Not a peptide; included for stack context. Zero published human trials. Long-term safety unknown.

Evidence levelExperimental
Regulatory statusResearch compound
DNA / pharmacogenomicsLow — NNMT expression varies; not yet a clinical PG marker.
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • DMechanistic / anecdotal

    5-Amino-1MQ — primary mechanism: small-molecule nnmt inhibitor (not a peptide). blocks nicotinamide n-methyltransferase to preserve cellular methyl-donor pools and nad+.

    1 supporting referencesVerified 5d ago
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    REVIEWFunding undisclosedVerified 5d ago
    PubMed — NNMT inhibition
RESEARCH GREYP-022

Research compound

5-Amino-1MQ50-150 mg · daily, oral
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesWho Stack is forFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.